TY - JOUR
T1 - Clinical characteristics and outcomes of hospitalized patients with heart failure from the large-scale Japanese registry of acute decompensated heart failure (JROADHF)
AU - Ide, Tomomi
AU - Kaku, Hidetaka
AU - Matsushima, Shouji
AU - Tohyama, Takeshi
AU - Enzan, Nobuyuki
AU - Funakoshi, Kouta
AU - Sumita, Yoko
AU - Nakai, Michikazu
AU - Nishimura, Kunihiro
AU - Miyamoto, Yoshihiro
AU - Tsuchihashi-Makaya, Miyuki
AU - Hatano, Masaru
AU - Komuro, Issei
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
H.T. reports receipt of scholarship funds from MSD, Astellas, Pfizer, Bristol-Myers Squibb, Otsuka Pharmaceutical, Daiichi-Sankyo, Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Takeda Pharmaceutical, Bayer Yakuhin, Novartis Pharma, Kowa Pharmaceutical, Teijin Pharma, Medical Review Co., and the Japanese Journal of Clinical Medicine; scholarship funds from Astellas, Novartis Pharma, Daiichi-Sankyo, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Teijin Pharma and MSD, outside of the submitted work.
Funding Information:
I.K. reports receipt of donations/scholarship funds from AstraZeneca K.K, Actelion Pharmaceuticals Japan Ltd., Astellas Pharma Inc., Amgen Astellas BioPharma K.K, ONO PHARMACEUTICAL CO., LTD., MSD K.K., Daiichi-Sankyo, Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd, BAYER YAKUHIN, LTD, Pfizer Japan Inc., and a research grant from ONO PHARMACEUTICAL CO., LTD., Meiji Co., Ltd., and a scholarship donation from KOWA Company, Ltd, Daiichi-Sankyo, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, TEIJIN PHARMA LIMITED, Nipro Corporation, and TERUMO CORPORATION.
Funding Information:
T.I. endowed chair funded by Actelion Pharmaceuticals. M.H. endowed chair from Otsuka Pharmaceutical Co., Ltd., Nipro Corporation, and TERUMO CORPORATION.
Funding Information:
This work was supported by the Japan Agency for Medical Research and Development grant (19ek0210097 h0003 (I.K.), 19ek0109339h0002 (H.T.), 19ek0210080h0003 (H.T.)), Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (17K09582 (T.I.), 15H04815 (H.T.)), and Health Labour Sciences Research Grant (20FC1051). The funders had no role in the design and conduct of the study or in collection, management, analysis and interpretation of the data, the preparation, review, and submission of the manuscript for publication.
Funding Information:
M.H. reports receipt of donations/scholarship funds from ONO PHARMACEUTICAL CO., LTD, and Daiichi-Sankyo, and a scholarship (educational) grant from Otsuka Pharmaceutical Co., Ltd., Nipro Corporation, and TERUMO CORPORATION.
Publisher Copyright:
© 2021 Japanese Circulation Society. All rights reserved.
PY - 2021/8/25
Y1 - 2021/8/25
N2 - Background: With aging population, the prevalence and incidence of heart failure (HF) have been increasing worldwide. However, the characteristics and outcomes of patients with HF in an era of aging are not well established in Japan. Methods and Results: The Japanese Registry Of Acute Decompensated Heart Failure (JROADHF), a retrospective, multicenter, nationwide registry, was designed to study the clinical characteristics and outcomes of patients hospitalized with HF throughout Japan in 2013. One hundred and twenty-eight hospitals were selected by cluster random sampling and 13,238 hospitalized patients with HF were identified by medical record review. Demographics, medical history, severity, treatment, and in-hospital and long-term outcome data were collected from the Diagnostic Procedure Combination and medical charts. Data were analyzed using univariate and multivariate logistic regression or Cox regression analysis. The mean age of registered patients was 78.0±12.5 years and 52.8% were male. Elderly patients (age >75 years) accounted for 68.9%, and HF with preserved ejection fraction (HFpEF) accounted for 45.1%. Median length of hospital stay was 18 days and in-hospital mortality was 7.7%. The median follow-up period was 4.3 years, and the incidence rates for cardiovascular death and rehospitalization for HF were 7.1 and 21.1 per 100 person-years, respectively. Conclusions: A contemporary nationwide registry demonstrated that hospitalized HF patients were very elderly, HFpEF was common, and their prognosis was still poor in Japan.
AB - Background: With aging population, the prevalence and incidence of heart failure (HF) have been increasing worldwide. However, the characteristics and outcomes of patients with HF in an era of aging are not well established in Japan. Methods and Results: The Japanese Registry Of Acute Decompensated Heart Failure (JROADHF), a retrospective, multicenter, nationwide registry, was designed to study the clinical characteristics and outcomes of patients hospitalized with HF throughout Japan in 2013. One hundred and twenty-eight hospitals were selected by cluster random sampling and 13,238 hospitalized patients with HF were identified by medical record review. Demographics, medical history, severity, treatment, and in-hospital and long-term outcome data were collected from the Diagnostic Procedure Combination and medical charts. Data were analyzed using univariate and multivariate logistic regression or Cox regression analysis. The mean age of registered patients was 78.0±12.5 years and 52.8% were male. Elderly patients (age >75 years) accounted for 68.9%, and HF with preserved ejection fraction (HFpEF) accounted for 45.1%. Median length of hospital stay was 18 days and in-hospital mortality was 7.7%. The median follow-up period was 4.3 years, and the incidence rates for cardiovascular death and rehospitalization for HF were 7.1 and 21.1 per 100 person-years, respectively. Conclusions: A contemporary nationwide registry demonstrated that hospitalized HF patients were very elderly, HFpEF was common, and their prognosis was still poor in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85112368532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112368532&partnerID=8YFLogxK
U2 - 10.1253/circj.CJ-20-0947
DO - 10.1253/circj.CJ-20-0947
M3 - Article
C2 - 33853998
AN - SCOPUS:85112368532
SN - 1346-9843
VL - 85
SP - 1438
EP - 1450
JO - Circulation Journal
JF - Circulation Journal
IS - 9
ER -